Also found in: Dictionary, Thesaurus, Wikipedia.


an immunomodulator used as a disease-modifying antirheumatic drug in treatment of rheumatoid arthritis, administered orally.


Apo-Leflunomide (CA), Arava, Novo-Leflunomide (CA), PMS-Leflunomide (CA), Sandoz Leflunomide (CA)

Pharmacologic class: Immune modulator

Therapeutic class: Antirheumatic

Pregnancy risk category X

FDA Box Warning

• Rule out pregnancy before starting therapy. Drug is contraindicated in pregnant women and in women of childbearing age who don't use reliable contraception. Caution patient to avoid pregnancy during therapy or before completing drug elimination procedure after treatment.

• Be aware that severe liver injury, including fatal liver failure, has been reported in some patients treated with leflunomide. Know that patients with preexisting acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) level of more than two times the upper limit of normal (ULN) before initiating treatment, shouldn't be treated with leflunomide. Use caution when giving drug with other potentially hepatotoxic drugs. Monitor ALT level at least monthly for first 6 months of therapy, and every 6 to 8 weeks thereafter. If ALT elevation is more than three times ULN, interrupt therapy while investigating the probable cause of the ALT elevation by close observation and additional tests. If ALT elevation is likely leflunomide-induced, start cholestyramine washout and monitor liver tests weekly until normalized. If leflunomide-induced liver injury is unlikely (because another probable cause has been found), resumption of therapy may be considered.


Inhibits T-cell pyrimidine biosynthesis, tyrosine kinases, and dihydroorotate dehydrogenase, blocking structural damage caused by inflammatory response to autoimmune process. Also shows analgesic, antipyretic, and histamine-blocking activity.


Tablets: 10 mg, 20 mg, 100 mg

Indications and dosages

Active rheumatoid arthritis

Adults: 100 mg P.O. daily for 3 days, then a maintenance dosage of 20 mg daily. If intolerance occurs, decrease to 10 mg daily.

Dosage adjustment

• Hepatic enzyme elevations


• Hypersensitivity to drug or its components

• Women who are or may become pregnant


Use cautiously in:

• renal insufficiency

• patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections (not recommended)

• new-onset or worsening pulmonary symptoms

• concurrent use of potentially hepatotoxic drugs

• concurrent use of live-virus vaccines (not recommended)

• men attempting to father a child

• breastfeeding patients

• children younger than age 18.


• Before starting drug, screen patients for latent tuberculosis (TB) infection with a tuberculin skin test. Treat patients who test positive for TB with standard medical practice before starting leflunomide.

• Obtain baseline platelet and white blood cell (WBC) counts, and hemoglobin or hematocrit.

• Check patient's blood pressure before starting leflunomide

• Give with or without food.

• Be aware that drug has a long half-life. To eliminate from bloodstream, give 8 g cholestyramine P.O. t.i.d. for 11 days.

Adverse reactions

CNS: headache, dizziness, asthenia

CV: chest pain, hypertension

EENT: rhinitis, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, gastroenteritis, mouth ulcers, anorexia

GU: urinary tract infection

Hematologic: pancytopenia, agranulocytosis, thrombocytopenia (rare)

Hepatic: hepatotoxicity

Metabolic: hypokalemia

Musculoskeletal: joint pain or disorders, back pain, leg cramps, synovitis, tenosynovitis

Respiratory: bronchitis, increased cough, pneumonia, respiratory infection, fatal interstitial lung disease

Skin: alopecia, rash, dry skin, eczema, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis

Other: weight loss, pain, infection, allergic reactions, flulike symptoms


Drug-drug. Activated charcoal, cholestyramine: rapid, steep drop in blood level of leflunomide's active metabolite

Methotrexate, other hepatotoxic drugs: increased risk of hepatotoxicity

Rifampin: increased blood level of leflunomide's active metabolite

Drug-diagnostic tests. Alanine aminotransferase (ALT), aspartate aminotransferase: increased levels

Hematocrit, hemoglobin, platelets, WBCs: decreased levels

Patient monitoring

• Check vital signs closely.

• Monitor platelet and WBC counts and hemoglobin or hematocrit monthly for 6 months after initiation of therapy and every 6 to 8 weeks thereafter. If evidence of bone marrow suppression occurs, discontinue drug and treat as indicated to reduce plasma concentration of leflunomide's active metabolite.

Watch for signs and symptoms of hepatotoxicity.

Be aware that rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in patients receiving leflunomide. If patient develops either condition, discontinue drug by using the recommended drug elimination procedure.

• Periodically assess cardiovascular status, including blood pressure, carefully to detect adverse reactions.

• Be aware that interstitial lung disease has been reported during leflunomide therapy and has been associated with fatal outcomes. New-onset or worsening pulmonary symptoms, such as cough and dyspnea with or without associated fever, may be cause for discontinuing drug and for further investigation as appropriate. If stopping drug is necessary, consider initiation of wash-out procedures.

• Monitor electrolyte levels.

• Monitor ALT level at least monthly for 6 months after starting drug, and every 6 to 8 weeks thereafter. If ALT level is more than three times the upper limit of normal, interrupt therapy while investigating the probable cause of the ALT elevation by close observation and additional tests. If leflunomide therapy is likely cause, start cholestyramine washout and monitor liver tests weekly until normalized. If leflunomide-induced liver injury is unlikely because another probable cause has been found, consider resuming drug therapy.

• Stay alert for signs and symptoms of infection. If a serious infection occurs, it may be necessary to interrupt therapy and administer cholestyramine or charcoal, as indicated.

• Observe patient closely after dosage reduction. Metabolite levels may take several weeks to fall.

Patient teaching

• Tell patient he may take with or without food.

Advise patient to immediately report unusual tiredness or yellowing of skin or eyes.

Instruct patient to recognize and report signs or symptoms of infection, respiratory problems, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

• Advise patient to avoid vaccination with live-virus vaccines.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Inform female of childbearing age that drug may harm fetus. Tell her to contact prescriber immediately if she suspects pregnancy.

• Caution female not to breastfeed without consulting prescriber.

• Advise male planning to father a child to consult prescriber, because drug may harm fetus.

• Tell patient he'll undergo regular blood testing to check liver function.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/le·flu·no·mide/ (lĕ-floo´no-mīd) an immunomodulator used in treatment of rheumatoid arthritis.


a pyrimidine synthesis inhibitor with anti-inflammatory effects.
indications It is used to treat rheumatoid arthritis.
contraindications Pregnancy, lactation, hepatic disease, jaundice, positive hepatitis B and C, severe immunosuppression, and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects include chest pain, angina pectoris, migraine, bronchitis, cough, respiratory infection, pneumonia, and sinusitis. Common side effects include nausea, anorexia, vomiting, constipation, flatulence, dizziness, insomnia, depression, paresthesia, palpitations, hypertension, rash, pruritus, pharyngitis, and rhinitis.


A disease-modifying anti-rheumatic drug used to treat rheumatoid arthritis. The drug has numerous possible side effects and may interact adversely with several other forms of treatment. It is used only under careful medical supervision by an expert. The drug has been suspected of causing serious lung complications since October 2003; a number of Japanese patients taking the drug have, since then, died from an interstitial pneumonia. Brand name: Arava.
References in periodicals archive ?
MTX and Leflunomide (LEF) remain a plausible option in this aspect.
sup][12] Patients were randomly assigned to Groups A (telmisartan [80 mg/d] + clopidogrel placebo + leflunomide placebo), B (telmisartan [80 mg/d] + clopidogrel [50 mg/d] + leflunomide placebo), and C (telmisartan [80 mg/d] + clopidogrel placebo + leflunomide [20 mg/d]), and 99 were assigned to Group D (telmisartan [80 mg/d] + clopidogrel [50 mg/d] + leflunomide [20 mg/d]).
Conclusion: There is no statistically significant difference between short term efficacy of Leflunomide and Methotrexate in patients with RA.
Remission of polyomavirus-induced graft nephropathy treated with lowdose leflunomide.
They were all given leflunomide to observe the clinical outcomes and whether HBV was activated.
Leflunomide is usually used as a replacement for mycophenolate.
Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis.
Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis.
17 patients of leflunomide group were treated with oral leflunomide l00 mg for first three days followed by 20 mg daily.
Prednisone was reduced to 5 mg, and leflunomide was washed out with cholestyramine.
Thomas Korn (Universitat des Saarlandes, Homburg, Germany) and his colleagues found that leflunomide prevented the development of EAE (experimental autoimmune encephalomyelitis), a disease similar to MS, in mice bred to be susceptible to it (Journal of Leukocyte Biology, 2004;76: 950).
Patients with ILD were more likely to be male, to smoke, and to have a history of prednisone and leflunomide use as well as rheumatoid factor and anti-CCP seropositivity compared with patients without ILD, said Dr.